Aytu BioScience Inc. recently presented clinical findings
for its MiOXSYS system at the 32nd annual meeting of the European
Society of Human Reproduction and Embryology.
Aytu BioScience is a
pharmaceutical company specializing in products for the urology field.
The company specifically created three posters that show the
potential of MiOXSYS to help diagnose male infertility. The system is a rapid
in vitro diagnostic system for the quantitative measurement of static
oxidation-reduction potential (sORP) in human semen.
“The medical and scientific community have long
understood that oxidative stress negatively impacts male fertility,” Josh
Disbrow, CEO of Aytu BioScience, said. “At the same
time, there has not been an easily accessible, rapid, in-office option to
measure oxidative stress in semen. Aytu has been committed to conducting
research to potentially validate the ability of the MiOXSYS system to fill this
gap.”
One poster concluded that semen failing at least one
parameter for normal semen contained higher amounts of oxidative stress. Another
came to similar results and suggested that measuring sORP could give users a
measure for confirming sperm morphology. The third poster dealt with Oxidation-reduction
Potential (ORP) of Spermatozoa Selected for Intracytoplasmic Sperm Injection
(ICSI).
